Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.

Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR.

Cancer Immunol Immunother. 2013 Apr;62(4):737-46. doi: 10.1007/s00262-012-1380-8. Epub 2012 Dec 7.

2.

Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.

Cabrera R, Ararat M, Eksioglu EA, Cao M, Xu Y, Wasserfall C, Atkinson MA, Liu C, Nelson DR.

Scand J Immunol. 2010 Oct;72(4):293-301. doi: 10.1111/j.1365-3083.2010.02427.x.

3.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL.

Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.

4.

Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.

Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M.

J Surg Oncol. 2013 Mar;107(4):422-7. doi: 10.1002/jso.23227. Epub 2012 Jul 25.

PMID:
22833259
6.

Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.

Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR.

Lab Invest. 2007 Jun;87(6):582-90. Epub 2007 Mar 19.

7.

Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.

Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, Qin LL, Wei L, Chen HS.

J Viral Hepat. 2010 Mar;17 Suppl 1:34-43.

PMID:
20586932
8.

[Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].

Wang ZH, Zhu JY, Li T, Leng XS.

Zhonghua Yi Xue Za Zhi. 2008 Mar 25;88(12):844-7. Chinese.

PMID:
18756991
9.

Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.

Cao M, Cabrera R, Xu Y, Liu C, Nelson D.

Int J Radiat Biol. 2011 Jan;87(1):71-80. doi: 10.3109/09553002.2010.518208. Epub 2010 Oct 20.

10.

The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells.

Sewgobind VD, Quaedackers ME, van der Laan LJ, Kraaijeveld R, Korevaar SS, Chan G, Weimar W, Baan CC.

Am J Transplant. 2010 Aug;10(8):1785-95. doi: 10.1111/j.1600-6143.2010.03200.x. Epub 2010 Jul 12.

11.

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS.

Gastroenterology. 2007 Jun;132(7):2328-39. Epub 2007 Apr 14.

PMID:
17570208
12.

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.

Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U.

Hepatology. 2013 Jun;57(6):2358-68. doi: 10.1002/hep.26328.

PMID:
23424039
13.

STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.

Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levings MK, Roncarolo MG, Bacchetta R.

Int Immunol. 2008 Mar;20(3):421-31. doi: 10.1093/intimm/dxn002. Epub 2008 Feb 12.

14.
15.

Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells.

Vercoulen Y, Wehrens EJ, van Teijlingen NH, de Jager W, Beekman JM, Prakken BJ.

PLoS One. 2009 Sep 25;4(9):e7183. doi: 10.1371/journal.pone.0007183.

16.

Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.

Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ.

Hepatology. 2005 Apr;41(4):722-30.

PMID:
15791620
17.

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.

Flörcken A, Takvorian A, Van Lessen A, Singh A, Hopfenmüller W, Dörken B, Pezzutto A, Westermann J.

Anticancer Drugs. 2012 Mar;23(3):298-302. doi: 10.1097/CAD.0b013e32834ee2b1.

PMID:
22156795
18.

Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma.

Feng X, Li B, Ye H, Long D.

Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):309-14. doi: 10.1007/s00005-011-0127-0. Epub 2011 Jun 3.

PMID:
21633918
19.

Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.

Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y.

J Hepatol. 2006 Aug;45(2):254-62. Epub 2006 Mar 9.

PMID:
16600416
20.

Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.

Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY.

PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8.

Items per page

Supplemental Content

Write to the Help Desk